Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol - Acrux/Gedeon Richter

Drug Profile

Estradiol - Acrux/Gedeon Richter

Alternative Names: Ellavie; Estradiol transdermal spray - Acrux; Evamist; Lenzetto

Latest Information Update: 29 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acrux
  • Developer Acrux; AMAG Pharmaceuticals; Gedeon Richter
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Vasomotor symptoms

Most Recent Events

  • 08 May 2019 Launched for Vasomotor symptoms in Poland, prior May 2019 (Transdermal)
  • 01 Dec 2016 Alvogen Pine Brook completes a phase III trial in Atrophic vaginitis in USA (NCT02995694)
  • 01 Apr 2016 Alvogen Pine Brook initiates enrolment in a phase III trial in Atrophic vaginitis in USA (NCT02995694)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top